Model-Based Strategy to Guide the Choice of Clinical Doses for ADC

Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving the therapeutic index, however the greatest challenge to date for developing ADCs is a narrow therapeutic window that often results in toxic effects occurring before an ADC reaches its maximally efficacious dose. The PK/PD scientists at Pierre Fabre have developed the novel modelling and simulation-based tools to guide the choice of the most promising safe and efficacious dosing regimen of an innovative antibody drug conjugate (ADC W0101). In this webinar, Dr Julie Desrivot Quénelle, the PKPD Project Lead at Pierre Fabre, will uncover the science behind the scenes and talk about model development characterizing: 1) The relationship between PK and tumor growth in xenograft mouse allowing to calculate the tumor-static concentrations (TSC), i.e. drug concentration leading to tumor volume stabilization. The comparison versus ADC PK parameters help to anticipate potential efficacious dosing regimen in human. 2) The ADC-induced toxicity in animal species and in patients. These models were further used to simulate potential patient outcomes, and to identify a safe dose range in clinical setting. Presenter: Julie Desrivot Quénelle, PKPD Project Lead, Pierre Fabre Host: Olivier Barberan, Director of Translational Medicine Solutions, Elsevier